DBT and TERI set up platform to orient nanobiotechnology research towards real-world solutions
- by Team ABLE - 14 Mar, 2019
The Department of Biotechnology (DBT), Government of India, and the TERI-Deakin Nanobiotechnology Centre (TDNBC) have set up Nanobiotech@DBT, India’s first platform to bring together the nanobiotechnology community and translate lab-based research into practical applications that benefit society.
On the occasion, Dr Ajay Mathur, Director General, TERI, said, “The idea is to convert research into scalable ideas that lead to the kinds of applications that farmers, doctors and others in allied areas need.”
Dr Alok Adholeya, Senior Director, Sustainable Agriculture division, TERI, added, “This platform is one of the key steps in bringing the nanobiotechnology community together to collaborate and share resources, information, knowledge, facilities, ideas, and infrastructure to create impactful and strategy driven research.”
TDNBC, which is implementing the Nanobiotech@DBT platform, will provide support from ideation to conceptualisation, implementation, incubation, and commercialisation. The platform will utilise both physical and virtual platforms for researchers and stakeholders to connect. It will be the first of its kind platform to bring all nanobiotechnology related research to a common platform and provide regular online updates on the DBT’s nanobiotechnology supported projects, nano-biocommunity, facilities and infrastructure, and related information and links. It will focus on five key areas of (i) Diagnostics & Imaging (ii) Nanomedicine & Therapeutics (iii) Delivery Vehicle (iv) Nanoenabled Systems & Devices; and (v) Agriculture, environment, nanotoxicology.
Dr Renu Swarup, Secretary, DBT, spoke about the platform at the International workshop on ‘Disruptive Translational Research in Nano-biotechnology: Advancing Sustainable Food Systems and Human Health Solutions’ in India Habitat Centre in New Delhi on Wednesday. The workshop was organised by Deakin University, Australia, in association with TERI and DBT.
“Translational research requires human resource, expenditure, deep domain research experience, and a whole ecosystem. Currently, there is a gap in translational research that we need to plug. Research is not getting translated into products. TDNBC, with its vast experience, is in a great place to do this,” Dr Swarup said in her keynote address at the event.
Stressing on the importance of regulation in product development, she added, “The DBT has made efforts and prepared guidelines for the pharmaceutical sector. TERI and other partners could do the same for agriculture sector. This will benefit not just regulators, but also innovators and the industry at large.”
Speaking on the Indo-Australian collaboration of TERI and Deakin University, she said, “We have to take partnership in this field beyond India and Australia. Going forward, it should be opened up to neighbouring countries. There are large opportunities for the Centre to provide leadership for research, capacity building, and innovation in translational research in the region.”
Rakesh Kapur, Joint Managing Director, Indian Farmers Fertilisers Cooperative Ltd, and a member of the governing board of TDNBC, delivered the guest of honour address at the event. He stressed that research has to be of use to the industry.
“As compared to conventional fertilisers, 20 per cent less nanofertilisers are required to be applied. With nanobiotechnology, there will be rapid disruptive change in the usage of fertilisers,” he said.
TDNBC too has been making progress in developing nanofertilisers. These nanonutrients are required in quantities of a few grams per acre as compared to bulk fertilisers that are required in kilograms per acre. TERI’s nanophosphorus, for example, uses nearly 10-20 times less phosphorous than bulk phosphorus fertilisers. Another nanofertiliser is being produced by recovering (through biological processes) zinc and iron from industrial waste. Both these products have tremendous promise for promoting sustainable agriculture in India.
At the workshop, Dr Adholeya also announced a collaboration with Aurea Systems, Germany, to launch TERI’s mycorrhiza products in India. Aurea has been marketing the product in North America and Europe and is set to enter the Indian market with this collaboration. Mycorrhiza is a biofertiliser that has the potential to reduce the use of chemical fertilisers globally by nearly 50 per cent.
A collaboration between TERI and Osho Resources India for bioreclamation of fly ash dumps, coal and coal waste dumps, and Acid Mine Drainage (AMD) was also announced. TERI has earlier successfully conducted bioremediation of abandoned fly ash dumps, wastelands contaminated with chlor alkali sludge, and reclaimed saline wastelands for cultivation of crops.
“Nanobiotechnology has opportunities in agriculture, health, food, and environment,” said John Stanhope AM, Chancellor, Deakin University, which is celebrating 25 years of its engagement with India. “When industries and research come together, they make a powerful team,” he added.
About TERI-Deakin Nanobiotechnology Centre
The TERI-Deakin Nanobiotechnology Centre was established with the mandate of developing innovative nanobiotechnology-based solutions to address current challenges in the field of agriculture and environment. It brings together the complimentary expertise of TERI in agriculture, biotechnology, green energy, bioremediation and nanotechnology and Deakin’s expertise in material, chemical and physical sciences. Jointly supported by both organisations, the Centre aims to take global space through the nanobiotechnology interventions in sustainable agriculture, environment, and energy by employing or developing multidisciplinary approaches, tools and technologies.
Charkit to Partner With Panacea Life Sciences on Hemp-Derived CBD Products
Global agreement covers distribution of Panacea Pure hemp oil, CBD isolates and CBD distillates to companies in the cosmetics, personal care and beauty industries.
NORWALK, Connecticut, March 13, 2019 /PRNewswire/ -- Jay Lang, President, Charkit Chemical Company, announced that the company has signed an exclusive representation agreement with Panacea Life Sciences of Golden, Colorado to distribute hemp-derived cannabidiol (CBD) products to the cosmetic and personal care industry.
With this agreement, Charkit will be responsible for the domestic and international distribution of Panacea Pure hemp oil and hemp-derived CBD isolates, distillates and blends produced at Panacea's 43,000 square foot Center of Excellence in Golden, Colorado. The facility features an impressive infrastructure, with advanced laboratories, proprietary extraction methods and GMP-compliant manufacturing processes. Panacea Pure hemp CBD isolate is guaranteed to be 99.9% pure and the company's CBD distillate is available in full spectrum, broad spectrum and varying concentrations to fit all production needs. All Panacea Pure hemp products are non-GMO, pesticide-free, herbicide-free and THC-free.
According to Dan O'Neill, Vice President and Sales Group Leader at Charkit, "Huge consumer demand, coupled with the recent passage of the US Farm Bill, means the market for CBD products is exploding. Our customers in cosmetic and personal care have a need for these products and we are now ready to supply them with high-quality, high-performance ingredients from Panacea."
Panacea (panacealife.com) is a market leader in developing medically relevant formulations and products from the hemp plant. The company sources industrial hemp grown organically in the USA, then processes it using proprietary extraction techniques to produce hemp oil that is rich in cannabinoids and terpenes. The oil is then further optimized and refined, including the removal of any detectable THC, resulting in material that is highly bioavailable. Until recently, that material has only been used in Panacea's own line of branded supplement products. With this announcement, it is now available for cosmetic and personal care applications through Charkit.
Nick Cavarra, Vice President of Sales and Marketing at Panacea stated that "Charkit's exemplary reputation and focus on working only with the top manufacturers in their respective industries aligns perfectly with Panacea's mission of providing the purest hemp CBD oil in the market. Their customer-centric approach, attention to detail, and the trust they have established in the cosmetics and personal care market made partnering with Charkit an easy decision."
The CBD industry, currently estimated at $800 million, is expected to grow to $19 billion by 2022. Because cannabinoid receptors are found throughout the human body, product applications in the skin care, sun care, personal hygiene and beauty segments represents a significant growth opportunity for manufacturers and marketers.
To find out more about Charkit's CBD ingredients, please send an email to: email@example.com.
The platform will focus on promoting translational research to convert nanobiotechnology research to practical applications